Trial End Points in Anti-neutrophil Cytoplasmic Antibody‑Associated Vasculitis
- 13 July 2026
- journal article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Kidney failure in patients with ANCA-associated vasculitis: A systematic review of outcomesAutoimmunity Reviews, 2026
- Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitisNature Reviews Rheumatology, 2025
- The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trialKidney International, 2024
- Albuminuria after induction treatment and kidney prognosis in ANCA-associated glomerulonephritisClinical Kidney Journal, 2024
- Data-driven subclassification of ANCA-associated vasculitis: model-based clustering of a federated international cohortThe Lancet Rheumatology, 2024
- Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohortThe Lancet, 2024
- Adding 6-month parameters for the prediction of kidney prognosis in ANCA-associated glomerulonephritisClinical Kidney Journal, 2023
- Avacopan for the Treatment of ANCA-Associated VasculitisNew England Journal of Medicine, 2021
- Developments in the Histopathological Classification of ANCA-Associated GlomerulonephritisClinical Journal of the American Society of Nephrology, 2020
- Modification and validation of the Birmingham Vasculitis Activity Score (version 3)Annals of the Rheumatic Diseases, 2009